lunes, 27 de octubre de 2025

For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat It is difficult to imagine a viable future for the biotech company following pause in trials

https://www.statnews.com/2025/10/27/intellia-therapeutics-crispr-impact/

No hay comentarios:

Publicar un comentario